601 related articles for article (PubMed ID: 29428943)
1. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
[TBL] [Abstract][Full Text] [Related]
2. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
4. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Onishi H; Nouso K; Nakamura S; Katsui K; Wada N; Morimoto Y; Miyahara K; Takeuchi Y; Kuwaki K; Yasunaka T; Miyake Y; Shiraha H; Takaki A; Kobayashi Y; Sakaguchi K; Kanazawa S; Yamamoto K
Hepatol Int; 2015 Jan; 9(1):105-12. PubMed ID: 25788384
[TBL] [Abstract][Full Text] [Related]
6. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Nagai H; Mukozu T; Ogino YU; Matsui D; Matsui T; Wakui N; Momiyama K; Igarashi Y; Sumino Y; Higai K
Anticancer Res; 2015 Apr; 35(4):2269-77. PubMed ID: 25862889
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
[TBL] [Abstract][Full Text] [Related]
10. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.
He MK; Zou RH; Li QJ; Zhou ZG; Shen JX; Zhang YF; Yu ZS; Xu L; Shi M
Cardiovasc Intervent Radiol; 2018 May; 41(5):734-743. PubMed ID: 29327075
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Kondo M; Morimoto M; Ishii T; Nozaki A; Fukuda H; Numata K; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Shibuya A; Okuse C; Suzuki M; Sakamaki K; Morita S; Maeda S; Tanaka K
J Dig Dis; 2015 Mar; 16(3):143-51. PubMed ID: 25495751
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
14. [Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
Tsukamoto T; Kanazawa A; Shimizu S; Murata A; Sakae M; Kurihara S; Tashima T; Deguchi S; Nakai T; Kawasaki Y; Kioka K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1878-80. PubMed ID: 26805203
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Miyaki D; Aikata H; Kan H; Fujino H; Urabe A; Masaki K; Fukuhara T; Kobayashi T; Naeshiro N; Nakahara T; Kawaoka T; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2013 Dec; 28(12):1834-41. PubMed ID: 23808713
[TBL] [Abstract][Full Text] [Related]
16. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
Nakazawa T; Hidaka H; Shibuya A; Okuwaki Y; Tanaka Y; Takada J; Minamino T; Watanabe M; Kokubu S; Koizumi W
BMC Gastroenterol; 2014 May; 14():84. PubMed ID: 24886354
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
Kang MK; Park JG; Lee HJ
Medicine (Baltimore); 2018 Apr; 97(17):e0611. PubMed ID: 29703062
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
19. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Kim GA; Shim JH; Yoon SM; Jung J; Kim JH; Ryu MH; Ryoo BY; Kang YK; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
J Vasc Interv Radiol; 2015 Mar; 26(3):320-9.e6. PubMed ID: 25612807
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
